A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Masanori Sato

ReachMed Partners LLC President

Masanori has extensive experience in pharmaceutical R&D, alliance management, and business development. Their career evolved into leadership roles in global product launches, strategic licensing, and early-stage clinical development, particularly in antiviral therapeutics at a R&D focused pharmaceutical division of a leading Japanese conglomerate. Later, as head of the business development department, they managed global licensing agreements and partnerships with major pharmaceutical companies in the U.S. and Europe for multiple in-house pipeline assets. Since 2016, they have held leadership roles in alliance management and business development at leading U.S. biotech and European pharmaceutical companies, focusing on partnerships with Japanese firms, contract negotiations, and search & evaluation of external technologies/assets across Japan and the Asia-Pacific region. From 2021, they joined a top Japanese pharmaceutical company, where they led open innovation initiatives, incubation of internal and external seed assets, and support for venture investments. During this time, they also served as a board member for a portfolio biotech companies. In March 2025, they founded their own company, leveraging their broad expertise and network to support Japanese biotech startups and assist international startups into Japan. They hold national license for Small and Medium Enterprise Management Consultant, among others.

Katsuhiro Fukunishi

Hiroyuki Kajiyama

Graduated from Kyoto University Faculty of Pharmaceutical Sciences. Worked at Tanabe Mitsubishi Pharma Corporation in pharmaceutical research and development, primarily handling clinical development tasks. Since 2016, employed at the Pharmaceuticals and Medical Devices Agency (PMDA), Review Management Department, as a Technical Expert in Regulatory Science Strategy Consultation. Engaged primarily in providing consultation services on pharmaceuticals, medical devices, regenerative medicine products, focusing on academia and venture companies.

Mineki Takechi

Cardio Intelligence Inc. Chief Development Officer
Director

After working at Fujitsu Ltd. on the development of products and services such as image processing system and cloud information service for home healthcare, as well as research and development in information retrieval and AI, and new business development, I engaged in the construction of a pulmonary hypertension patient registry at the International University of Health and Welfare Mita Hospital. Since 2020, I have been serving as CDO at Cardio Intelligence Inc., responsible for the development of software medical devices for arrhythmia analysis and regulatory affairs. Since 2021, I have also been serving as COO, overseeing overall business planning and execution.

Takahiro Mizumoto

Ant innovations Co., Ltd

Kyoto University Graduate School of Medicine, Master’s Program in Intellectual Property Management.
After passing the Japanese Patent Attorney Examination, gained venture investment experience in high-tech sectors including IT and healthcare at NIFS SMBC Capital (later split into Daiwa Corporate Investment and SMBC Venture Capital).
Subsequently joined Showa Shell Sekiyu, where he led the planning and development of multiple new services spanning payment solutions, retail electricity, and mobile app businesses. With the launch of the University of Tokyo Innovation Platform (UTokyo IPC), he joined the firm and founded 1stRound, a cross-university incubation program. He later spearheaded the establishment of an approximately JPY 25 billion open-innovation promotion fund and served as its Chief Investment Officer.
In November 2025, he founded Ant Innovations, a newly established venture capital firm and subsidiary of the private equity firm Ant Capital Partners, and assumed the role of Representative Director and Partner.